Abstract
The present study was carried out to elucidate the mechanisms behind an increase in the incidence of malignant or multiple mammary tumors as a result of oral administration of rolipram in a 104-week carcinogenicity study. The organs and tissues of Sprague-Dawley (SD) rats of both sexes, which had been subjected to a 104-week oral carcinogenicity study at doses of 0.2, 0.6 and 2.0 mg/kg, were examined. No treatment-related effects were seen in males; however, in females, there was a significant increase in the number of malignant or multiple mammary tumor bearers at a dose of 2.0 mg/kg. No other target organs were identified and the incidence of other tumor types were within the female control range. To clarify the mechanisms behind a rolipram-induced increase in the incidence of mammary adenocarcinoma at time points earlier than 104 weeks, the hormonal changes associated with pituitary adenoma were identified, and estrous cycling in the ovary, uterus, and vagina were examined in female rats treated with rolipram for 52 weeks. The plasma prolactin (PRL) concentration in all female groups exceeded the control value at Week 52, and all these differences were statistically significant. There was also a dose-dependent relationship with PRL-producing pituitary adenomas. Changes in estrous cycling in the uterus and vagina and a decrease in the size and number of corpora lutea in the ovaries of female rats treated with rolipram at 2.0 mg/kg for 52 weeks indicated that an increase in the estrus phase of the cycle corresponded to a marked decrease in the diestrus phase, which might result from the increased plasma estrogen concentration. Together, all of the above mentioned data suggest that rolipram not only stimulates an increase in the number and size of PRL adenomas in the pituitary gland but also in the estrus phase of the estrous cycle. These events might cause progression of the mammary gland tissues from hyperplasia to carcinoma.
This is a preview of subscription content, log in via an institution to check access.
References
Brockman JL, Schroeder M, Schuler LA (2002) Prolactin activates the cyclin D1 promoter via the JAK2-STAT pathway. Mol Endocrinol 16:774–784
Brown D (1990) ZK 62.711 (rolipram) 104-week oral dietary administration carcinogenicity and toxicity study in the rat. Hazleton England Report No 5776:14/38
Clevenger CV, Furth PA, Hankison SE, Schuler LA (2003) The role of prolactin in mammary carcinoma. Endocrin Rev 24(1):1–27
Gordeladze JO (1990) The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells. Bioscience Rep 10(4):375–388
Harvell DM, Strecker TE, Tochacek M, Xie B, Pennington KL, McComb RD, Roy SK, Shull JD (2000) Rat strain-specific actions of 17β-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasis and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci USA 97(6):2779–2784
Ito N (1986) The reproductive organs of female. In: Ito N (ed) Color atlas of experimental animal histology. Sofutosaiensu-sha, Tokyo, pp 174–199
Ito S (1979) Hormones from the ovary. In: Ito S (ed), Endocrinology. Rikogaku-sha, Tokyo, pp 199–227
Khater R (1990) ZK 62.711 (rolipram) tumorigenicity study in mice using dietary administration over 100–101 weeks. Schering Report No. 8759
LIoyd RV (1983) Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. An immunohistochemical study. Am J Pathol 113(2):198–206
Nagasawa H (1984) Prolactin and mammary carcinoma. In: Kuratomo KI (ed), Prolactin. Nanzando, Tokyo, pp 216–226
Spady TJ, Harvell DME, Snyder MC, Pennington KL, McComb RD, Shull JD (1998) Estrogen-induced tumorigenesis in the Copenhagen rat: disparate susceptibilities to development of prolactin-producing pituitary tumors and mammary carcinomas. Cancer Let 124:95–103
Umemura S, Iwasaka T, Kakimoto K, Takahashi A, Koizumi H, Miyakawa Y, Kurotani R, Osamura RY (2001) Expression of prolactin gene in spontaneous mammary tumors in aging Fischer 344 rats. Endocr J 48(5):597–602
Yuan Y-D (1991) The female reproductive system. In: Hascheck WM, Rousseaux GG (eds) Handbook of toxicologic pathology. Academic Press, New York, pp 891–935
Acknowledgements
This study was performed in cooperation with Meiji Seika Kaisha, Ltd. and Schering AG. We gratefully acknowledge the assistance of Drs Bernhard Fritzzieroth and Fred Siegmund of Schering AG regarding the use of the results of the 104-week oral carcinogenicity and toxicity study. We thank Drs Yoshihisa Nakano and Hiroki Akiyama of Meiji Seika Kaisha, Ltd for their advice regarding the pathological and statistical analysis. This study complies with the current laws of Japan where the experiments were performed.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was performed in Meiji Seika Kaisha LTD and Schering AG.
Rights and permissions
About this article
Cite this article
Nishiyama, S., Okudaira, M. & Saito, N. Mechanisms of rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats. Arch Toxicol 80, 88–97 (2006). https://doi.org/10.1007/s00204-005-0016-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-005-0016-6